Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL – Research Report), Insmed ...

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Insmed (INSM) and Orchestra BioMed Holdings (OBIO)

Clear Street analyst William Maughan maintained a Buy rating on Ocular Therapeutix today and set a price target of $21.00. According to TipRanks, M...

Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

Ocular Therapeutix ( ($OCUL) ) has shared an announcement. Ocular Therapeutix plans to submit a new drug application for its product candidate AXPA...

Ocular Therapeutix Prepares NDA Submission for Wet AMD Drug

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX – Research Report...

Current Quarter	$-0.33	Next Quarter	$-0.33
Current Year	$-1.44	Next Year	$-1.38
QoQ Growth	+0.0%	YoY Growth	+4.2%
3Y EPS CAGR	-138.4%	Target Price	$22.08
Consensus	Buy	Upside	+51.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCUL	$14.56	-0.75%	2.83M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OCUL	$14.56	-0.7%	2.83M
3
4
5
6

OCUL

OCUL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ocular Therapeutix Inc. Data in Excel

Get Ocular Therapeutix Inc. Data in Excel